Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Symbyax: Difference between revisions

From Pharmacopedia
[unchecked revision][unchecked revision]
parser-claude batch MedTemplate pre-fill, mind-medicine combination
 
parser-claude housekeeping, em-dash to comma per style rule
Line 16: Line 16:
| pregnancy        = Limited data; fluoxetine has reassuring data but olanzapine carries metabolic-syndrome and gestational diabetes signals.{{citation needed}}
| pregnancy        = Limited data; fluoxetine has reassuring data but olanzapine carries metabolic-syndrome and gestational diabetes signals.{{citation needed}}
| legal            = [[USLegal:Prescription only|Rx-only]] in US. Carries the '''antidepressant Boxed Warning''' for suicidality in children/adolescents/young adults and the atypical-antipsychotic '''Boxed Warning''' for increased mortality in elderly dementia patients<ref name="symbyax-label" />
| legal            = [[USLegal:Prescription only|Rx-only]] in US. Carries the '''antidepressant Boxed Warning''' for suicidality in children/adolescents/young adults and the atypical-antipsychotic '''Boxed Warning''' for increased mortality in elderly dementia patients<ref name="symbyax-label" />
| mechanism        = <vote slug="symbyax-mech-claim">Olanzapine is a thienobenzodiazepine atypical neuroleptic with D2, 5-HT2A/2C, H1, M1, and α1 antagonism, providing both antimanic effect and adjunctive mood-stabilization. Fluoxetine is a selective serotonin reuptake inhibitor with antidepressant effect. The combination addresses the dual challenge of bipolar depression risk of antidepressant-induced manic switch and inadequate response to mood stabilizer monotherapy by pairing the fluoxetine antidepressant with the olanzapine mood-stabilizing/antimanic anchor.</vote> Metabolic effects (weight gain, dyslipidemia, glucose dysregulation) dominate the long-term tolerability profile; routine metabolic monitoring is standard<ref name="symbyax-label" />.
| mechanism        = <vote slug="symbyax-mech-claim">Olanzapine is a thienobenzodiazepine atypical neuroleptic with D2, 5-HT2A/2C, H1, M1, and α1 antagonism, providing both antimanic effect and adjunctive mood-stabilization. Fluoxetine is a selective serotonin reuptake inhibitor with antidepressant effect. The combination addresses the dual challenge of bipolar depression, risk of antidepressant-induced manic switch and inadequate response to mood stabilizer monotherapy, by pairing the fluoxetine antidepressant with the olanzapine mood-stabilizing/antimanic anchor.</vote> Metabolic effects (weight gain, dyslipidemia, glucose dysregulation) dominate the long-term tolerability profile; routine metabolic monitoring is standard<ref name="symbyax-label" />.
}}
}}


== References ==
== References ==
<references />
<references />